Systematic Approach for the Formulation and Optimization of Solid Lipid Nanoparticles of Efavirenz by High Pressure Homogenization Using Design of Experiments for Brain Targeting and Enhanced Bioavailability

Table 5

(a) Response Surface Quadratic Model for particle size ( < 0.0001). (b) Response Surface Quadratic Model for PDI ( = 0.0272).

(a)

Response 1—PS (particle size); ANOVA for Response Surface Quadratic Model; Analysis of Variance table (partial sum of squares—Type III)
Source	Sum of; squares	df	Mean; square	value	value; Prob >
Model	64116.53	5	12823.31	42.26	<0.0001	Significant
—pressure	49886.40	1	49886.40	164.42	<0.0001	Significant
—number of cycles	10061.42	1	10061.42	33.16	0.0007	Significant
	549.90	1	549.90	1.81	0.2202	Not significant
	2681.72	1	2681.72	8.84	0.0207	Significant
	73.55	1	73.55	0.24	0.6375	Not significant
Residual	2123.88	7	303.41	—	—	—
Lack of fit	1634.49	3	544.83	4.45	0.0915	Not significant
Pure error	489.39	4	122.35	—	—	—
Cor total	66240.41	12	—	—	—	—

(b)

Response 2—PDI (polydispersity index); ANOVA for Response Surface Quadratic Model; Analysis of Variance table (partial sum of squares—Type III)
Source	Sum of; squares	df	Mean; square	value	value; Prob >
Model	0.049	5		5.11	0.0272	Significant
—pressure	0.010	1	0.010	5.37	0.0536	Not significant
—number of cycles	0.023	1	0.023	12.18	0.0101	Significant
						Not significant
						Not significant
	0.014	1	0.014	7.25	0.0310	Significant
Residual				—	—	—
Lack of fit				0.72	0.5899	Not significant
Pure error				—	—	—
Cor total	0.063	12	—	—	—	—